Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
CanadaIPO:
09 May 2019Website:
http://www.milestonepharma.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 26 Jun 2024 23:22:38 GMTDividend
Analysts recommendations
Institutional Ownership
MIST Latest News
MONTREAL and CHARLOTTE, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that the United States Food and Drug Administration (FDA) accepted the Company's New Drug Application (NDA) on May 26, 2024 for CARDAMYST (etripamil) nasal spray, its lead investigational product for the management of paroxysmal supraventricular tachycardia (PSVT). The FDA Prescription Drug User Fee Act (PDUFA) target date is 10 months from the acceptance date of May 26, 2024.
Milestone Pharmaceuticals (MIST) has been upgraded to a Zacks Rank #2 (Buy), indicating increasing confidence in the company's earnings outlook. This could lead to a potential rise in the stock price in the short term.
Milestone Pharmaceuticals (MIST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Milestone Pharma (MIST) plunges 31% following an RTF letter from the FDA due to insufficient data to begin a substantive review of the regulatory filing for etripamil nasal spray to treat PSVT.
Today, we take a deeper look at Milestone Pharmaceuticals Inc. for the first time on Seeking Alpha. The company's primary drug candidate has a novel delivery system and should have an NDA submitted around it next quarter.
What type of business is Milestone Pharmaceuticals?
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
What sector is Milestone Pharmaceuticals in?
Milestone Pharmaceuticals is in the Healthcare sector
What industry is Milestone Pharmaceuticals in?
Milestone Pharmaceuticals is in the Biotechnology industry
What country is Milestone Pharmaceuticals from?
Milestone Pharmaceuticals is headquartered in Canada
When did Milestone Pharmaceuticals go public?
Milestone Pharmaceuticals initial public offering (IPO) was on 09 May 2019
What is Milestone Pharmaceuticals website?
https://www.milestonepharma.com
Is Milestone Pharmaceuticals in the S&P 500?
No, Milestone Pharmaceuticals is not included in the S&P 500 index
Is Milestone Pharmaceuticals in the NASDAQ 100?
No, Milestone Pharmaceuticals is not included in the NASDAQ 100 index
Is Milestone Pharmaceuticals in the Dow Jones?
No, Milestone Pharmaceuticals is not included in the Dow Jones index
When does Milestone Pharmaceuticals report earnings?
The next expected earnings date for Milestone Pharmaceuticals is 09 August 2024